Samsung Biologics' PolyPeptide Tender Window Opens Today: What the CHF 1.46 Billion Bid Means for Peptide API Supply

Key takeaways

• The formal acceptance period for Samsung Biologics' all-cash public tender offer for PolyPeptide Group AG opened today, 15 September 2026, and is scheduled to run until 12 October 2026.
• The offer values PolyPeptide at approximately CHF 1.46 billion (roughly USD 1.81 billion), representing a 40% premium to the company's unaffected share price.
• PolyPeptide's largest individual shareholder, Draupnir Holding B.V., has committed to tender its approximately 55.65% stake, materially increasing the likelihood that the 66⅔% minimum acceptance threshold will be reached.
• If completed, Samsung Biologics — presently focused on antibody manufacturing — would acquire one of the small number of CDMOs with validated, commercial-scale solid-phase peptide synthesis (SPPS) infrastructure at multiple sites across Europe, the United States, and India.
• The transaction follows CordenPharma's completed acquisition of AmbioPharm on 3 August 2026, accelerating a wave of consolidation among the handful of organisations capable of producing pharmaceutical-grade peptide active pharmaceutical ingredients (APIs) at commercial scale.

The offer in detail

Samsung Biologics published the formal offer prospectus on 31 August 2026, acting through its direct Swiss subsidiary Samsung Peptide AG. The prospectus followed a ten-trading-day cooling-off period on the SIX Swiss Exchange that began on 1 September 2026, as required under Swiss takeover law.

Under the offer terms, PolyPeptide shareholders receive CHF 44.31 net in cash per share, representing an implied aggregate equity value of approximately CHF 1.46 billion. The offer price also represents an approximately 11.6% premium to the volume-weighted average share price over the 60 trading days prior to Samsung's pre-announcement on 20 July 2026.

PolyPeptide's board, acting through its independent and non-conflicted members, unanimously recommended that shareholders accept the offer, a recommendation supported by an independent fairness opinion from IFBC AG. The offer is subject to a minimum acceptance threshold of 66⅔% on a fully diluted share-count basis, applicable regulatory approvals, and other customary conditions. Following settlement, Samsung Peptide intends to pursue a squeeze-out of any remaining minority shareholders and to delist PolyPeptide's shares from the SIX.

Samsung Biologics financed the acquisition through a 3 trillion Korean won (approximately USD 2.2 billion) rights offering, of which 2.7062 trillion won is allocated to the PolyPeptide purchase, with the remainder earmarked for expansion of its second Bio Campus in Songdo and related projects.

What PolyPeptide brings to the table

Founded in 1952 and headquartered in Baar, Switzerland, PolyPeptide operates six cGMP-certified manufacturing sites across Europe, the United States, and India. The company has produced over 1,000 GMP-quality peptides and is described by third-party industry sources as manufacturing approximately half of commercially approved peptide APIs globally — a claim that, if accurate, makes its infrastructure strategically significant in the current GLP-1-driven demand environment.

Key assets include:

• A large-scale SPPS facility in Braine-l'Alleud, Belgium — a €100 million investment described by the company as the single largest in its 70-year history — which reached target utilisation by end of 2025 and is understood to serve a long-term commercial agreement expected to generate approximately €100 million in annual orders at full ramp.
• A capacity expansion project in Malmö, Sweden, where pre-built SPPS modules have been delivered and installed, currently undergoing mechanical completion.
• Newly added SPPS capacity in Strasbourg, France, now operational and expected to ramp production throughout 2026.
• A facility in Torrance, California, serving North American pharmaceutical customers.
• A planned expansion at the Ambernath, India facility, intended to transform it into a larger, more diversified site.

In its 2025 annual report, PolyPeptide estimated the addressable outsourced market for synthetically manufactured peptide-based APIs at approximately USD 2.5 billion in 2024. The company positions itself as serving pharmaceutical and biotech customers from pre-clinical through to commercial stages under cGMP, in compliance with ICH guidelines.

Strategic rationale: why SPPS capacity is the scarce resource

Samsung Biologics has characterised the deal as central to its "multi-modality strategy" — an ambition to extend beyond its established antibody contract manufacturing business into peptides and, by implication, the GLP-1 API supply chain. With demand for peptides rising sharply as the obesity treatment market expands, analysts have described the move as securing a new growth axis that complements rather than replicates its existing biologics portfolio.

The underlying logic is infrastructure scarcity. Commercial-scale SPPS capacity — the primary manufacturing route for GLP-1 active pharmaceutical ingredients such as semaglutide and tirzepatide peptide analogues — cannot be constructed on a short timeline. Regulatory validation of new peptide API facilities typically requires several years. Acquiring an existing, validated network is therefore the fastest credible route to meaningful capacity. The same reasoning appears to have driven CordenPharma's acquisition of AmbioPharm, completed on 3 August 2026, which added AmbioPharm's South Carolina and Shanghai facilities to CordenPharma's existing European peptide network.

Taken together, these two transactions mean that a significant proportion of the world's commercial-scale, GMP-validated peptide synthesis capacity is in the process of changing hands within a single quarter.

Parallel capital flows: the oral peptide investment wave

The consolidation at the CDMO tier is running in parallel with sustained venture investment in peptide drug discovery platforms. Syneron Bio, a Beijing-based macrocyclic peptide company, closed a USD 150 million Series B in April 2026, four months after its Series A, to support its AI-driven Synova peptide platform. The round included participation from AstraZeneca, the Abu Dhabi Investment Authority, and several Asia-focused life sciences funds.

Pinnacle Medicines, an OrbiMed-incubated biotech with offices in Shanghai and Doylestown, Pennsylvania, closed an oversubscribed USD 89 million Series B to advance its oral peptide pipeline through clinical proof of concept. The company uses an AI- and physics-based platform to design orally bioavailable peptide drugs, with initial focus on immunology and cardiometabolic diseases, and its lead programme is reported to be on track to enter the clinic in asthma and COPD.

These investments reflect a broader industry thesis: that the peptide format — historically constrained by poor oral bioavailability and the need for injectable delivery — is approaching an inflection point through combination of structural chemistry innovation and AI-assisted molecular design.

Procurement implications for UK research laboratories

For UK procurement professionals sourcing pharmaceutical-grade peptide APIs or research-grade material from CDMO-linked supply chains, the current period warrants active monitoring on two fronts.

Supply continuity. Acquisitions of this size typically carry an 18-to-24-month period of operational integration. During that window, pricing frameworks, minimum order quantities, lead times, and customer-facing account management structures may change. Existing supply agreements with PolyPeptide Group should be reviewed against force majeure and change-of-control provisions. Laboratories with active cGMP material supply agreements are advised to seek written confirmation from PolyPeptide account managers regarding the continuity of batch release timelines and quality system certifications through the integration phase.

Concentration risk. The simultaneous acquisition of PolyPeptide (by Samsung Biologics) and AmbioPharm (by CordenPharma) reduces the number of independently operated, commercial-scale peptide CDMO platforms. Procurement teams reliant on competitive tendering across those providers should begin mapping alternative qualified suppliers — including Bachem, Polypeptide's Swedish competitor, and Lonza's peptide synthesis division — before consolidation alters the competitive dynamics.

Regulatory continuity. Both PolyPeptide and AmbioPharm hold cGMP certifications from multiple regulatory authorities, including the EMA and the FDA. These certifications attach to individual sites and manufacturing processes, not to corporate ownership. However, post-acquisition site audits by new parent companies can introduce re-qualification cycles. UK laboratories importing peptide APIs subject to MHRA oversight should confirm that the relevant site's manufacturer authorisation status has not been placed under review during the transition period.

The Samsung Biologics tender offer prospectus and all supporting documentation are available at samsungbiologics.com/offer. The acceptance period runs until 12 October 2026, with transaction closing targeted towards the end of 2026 subject to regulatory approvals.